{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"16"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"3"}]}],"title":"Worsened From Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"1"}]}],"title":"Improved From Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"22"},{"groupId":"OG007","value":"21"},{"groupId":"OG008","value":"4"}]}],"title":"Total"}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"50"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"79"},{"groupId":"OG007","value":"64"},{"groupId":"OG008","value":"24"}],"units":"Participants"}],"description":"Number of participants whose chest X-ray results changed (worsened or improved) from the Baseline.","groups":[{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG000","title":"Bosutinib 500 mg, CP2L-CML IM-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG001","title":"Bosutinib 500 mg, CP2L-CML IM-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I, D and NI R/I or IM R/I and NI-I CML.","id":"OG002","title":"Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-R CML.","id":"OG003","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-I CML.","id":"OG004","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and NI-R CML.","id":"OG005","title":"Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)"},{"description":"All participants who received bosutinib 500 mg orally once daily in AP CML who were IM R/I or multiple tyrosine kinase inhibitor (Multi-TKI): IM, D and/or NI R/I.","id":"OG006","title":"AP-CML Total (Part 2)"},{"description":"All participants who received bosutinib 500 mg orally once daily in blast phase (BP) CML who were IM R/I or Multi-TKI: IM, D and/or NI R/I.","id":"OG007","title":"BP-CML Total (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with Ph+ ALL","id":"OG008","title":"Bosutinib 500 mg, Ph+ ALL (Part 2)"}],"paramType":"NUMBER","populationDescription":"Safety population included all participants who received at lease one dose of study medication.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 8, and end of treatment","title":"Number of Participants With Change From Baseline in Findings of Chest X-ray","type":"SECONDARY","unitOfMeasure":"participants"}